Abstract #0230

Amide-Proton-Transfer-Weighted (APTw) MRI as a Surrogate Biomarker to Detect Recurrent High-grade Gliomas after Treatment with Chemoradiation: Validation by Image-Guided Stereotactic Biopsy

Shanshan Jiang^1,2, Charles Eberhart³, Jaishri Blakeley⁴, Lindsay Blair⁴, Huamin Qin ³, Michael Lim⁵, Alfredo Quinones-Hinojosa⁵, Hye-Young Heo¹, Yi Zhang¹, Dong-Hoon Lee¹, Xuna Zhao¹, Zhibo Wen², Peter C.M. van Zijl¹, and Jinyuan Zhou¹

¹Department of Radiology, Johns Hopkins University, Baltimore, MD, United States, ²Department of Radiology, Southern Medical University Zhujiang Hospital, Guangzhou, China, People's Republic of, ³Department of Pathology, Johns Hopkins University, Baltimore, MD, United States, ⁴Department of Neurology, Johns Hopkins University, Baltimore, MD, United States, ⁵Department of Neurosurgery, Johns Hopkins University, Baltimore, MD, United States

We explored the imaging features of treatment effects and active tumor in glioma patients after surgery and chemoradiation using amide-proton-transfer-weighted (APTw) imaging at 3 Tesla. Needle biopsy samples were obtained for pathological validation. Corresponding APTw signal intensities were recorded. Results showed that APTw signal intensities had strong positive correlations with cellularity and proliferation. The active tumor had significantly higher APTw signal intensity, compared to treatment effects. The area-under-curve (AUC) for APTw intensities to differentiate treatment effects from active tumor was 0.959. APT imaging has potential for molecular image-guided biopsy for post-treatment glioma patients to distinguish pseudoprogression from tumor recurrence.

This abstract and the presentation materials are available to members only; a login is required.

Join Here